Gérard J, Luyckx A S, Lefèbvre P J
Int J Clin Pharmacol Ther Toxicol. 1984 Jan;22(1):25-31.
This study investigates the effect of Acarbose, a complex oligosaccharide of microbial origin with glucosidase-inhibiting properties in alimentary hypoglycemia secondary to rapid gastric emptying and in reactive hypoglycemia either isolated or associated with impaired glucose tolerance. Twenty-four patients complaining of symptoms suggesting hypoglycemia which occurred after meals and who showed blood glucose values of 2.5 mmol/l (45 mg/dl) or below on one or more occasions during a 5-h oral glucose tolerance test were selected and divided into three groups. Group I comprized seven patients with demonstrated rapid gastric emptying; group II comprized eight patients with impaired glucose tolerance, whereas the nine patients of group III were considered to present with "isolated reactive hypoglycemia" since they had a normal glucose tolerance and did not have either glycosuria or gastroduodenal pathology. All patients were submitted to two oral 75-g sucrose tolerance tests. Acarbose (100 mg) or placebo was ingested with the first drought of the sucrose solution administered in a randomized order. The investigation was performed in a double-blind manner. In all three groups Acarbose significantly reduced the magnitude of post-sucrose reactive hypoglycemia. The blood glucose nadir also occurred later, but this effect was statistically significant in group II only. In patients of groups II and III, such improvement of the glucose nadirs was preceded by a significant reduction of the post-sucrose glycemic peak. In all three groups, the insulin response to oral sucrose was reduced by Acarbose. Another consistent finding was the lack of sucrose-induced glucagon suppression when Acarbose was given. These data suggest that Acarbose might be a useful adjunct to the management of functional hypoglycemia.
本研究调查了阿卡波糖的作用,阿卡波糖是一种微生物来源的复合寡糖,具有葡萄糖苷酶抑制特性,用于治疗继发于胃排空过快的食饵性低血糖以及孤立性或与糖耐量受损相关的反应性低血糖。选取了24例餐后出现提示低血糖症状且在5小时口服葡萄糖耐量试验期间有一次或多次血糖值低于2.5 mmol/l(45 mg/dl)的患者,并将其分为三组。第一组包括7例已证实胃排空过快的患者;第二组包括8例糖耐量受损的患者,而第三组的9例患者被认为患有“孤立性反应性低血糖”,因为他们糖耐量正常,且没有糖尿或胃十二指肠病变。所有患者均接受两次口服75 g蔗糖耐量试验。阿卡波糖(100 mg)或安慰剂以随机顺序与第一次给予的蔗糖溶液一起服用。研究采用双盲方式进行。在所有三组中,阿卡波糖均显著降低了蔗糖后反应性低血糖的程度。血糖最低点出现的时间也较晚,但仅在第二组中该效应具有统计学意义。在第二组和第三组患者中,血糖最低点的这种改善之前,蔗糖后血糖峰值显著降低。在所有三组中,阿卡波糖均降低了口服蔗糖后的胰岛素反应。另一个一致的发现是,给予阿卡波糖时,蔗糖诱导的胰高血糖素抑制作用缺乏。这些数据表明,阿卡波糖可能是功能性低血糖管理的有用辅助药物。